DERM Flashcards
What is xerosis
dry skin
Xerosis treatment
Emollients
* first line for ___
* restores barrier and skin ___
itching
function
Agents to reduce itching
menthol and camphor
* ___ sensation
pramoxine
* local ___
aluminum acetate
* alter C-fiber ___ transmission hydrocortisone
* anti- ___
- cooling
- anesthetic
- nerve
- inflammatory
Dermatitis - Inflammatory process of the upper
___ layers of skin
2
acute dermatitis
- itching is ___
- ___ dermatitic
- poison ivy
- 2 types: ___ and ___
- intense
- contact
- allergic and irritant
sub-acute dermatitis
- itching is common but less ___
- ___ dermatitis
- intense
- atopic
chronic dermatitis
- lichenification
- ___ dermatitis
stasis
Acute Contact Dermatitis
Irritant - non ___ reaction to frequent contact with everyday substances
* more common than allergic
* reaction within a few ___
- immunologic
- hours
Contact Dermatitis - Poison Ivy
T or F: poison ivy does not spread from lesions
True
Contact Dermatitis - Poison Ivy
* ___ is key
* Ivy-Block - reapply every ___ hours
* topical therapy OK if less than ___ % BSA involved
* Treat with: ___ lotion, topical or oral antihistamines, topical or oral corticosteroids
- prevention
- 4
- 10%
- calamine
T or F: corticosteroid dose packs are first line therapy for acute dermatitis
False; do not provide treatment for long enough
Treatment of acute dermatitis
prednisone ___ mg per day; taper every ___ days
* minimum of ___ days of treatment
- 40-60 mg
- 3 days
- 10-14 days
Atopic Triad
- atopic dermatitis
- allergic rhinitis
- asthma
atopic dermatitis
Pruritis
symmetrical red papules or plaques
Topical Corticosteroids
Classified according to potency which corresponds to ___ activity and ___ potency
* only ___ % absored when applied to normal intact skin
* vehicle impacts delivery and ___ of corticosteroids
- anti-inflammatory
- vasoconstrictive
- 2%
- potency
Side effects of topical corticosteroids
* ___ of skin
* ___ blood vessels
* ___ bruising
* skin ___ changes
* development of ___ (tachyphylaxis)
* risk of ___ suppression with long term use of high potency agents
- thinning
- dialated
- increased
- color
- tolerance
- HPA
Topical Corticosteroids
very high potency class 1
* betamethasone dipropionate ___
* halobetasol proprionate
* clobetasone proprionate
* do not use on ___
* do not use longer than ___ weeks
* no more than ___ grams per week
- ointment
- face
- 2 weeks
- 50 grams
Topical Corticosteroids
high potency class 2
* betamethasone dipropionate ___
* fluocinolide
* same comments as very high potency class 1
cream
Topical Corticosteroids
mid potency classes 3-5
* triancinolone acentonide
* mometasone furoate
* betamethasone dipropionate ___
* used on mores skin surfaced for exacerbations
* moderate ___ effect
* safer for ___ term useage
* dont use long term on ___
- lotion
- anti-inflammatory
- long
- face
Topical Corticosteroids
low potency calsses 6-7
* ___
* desonide
* can use on ___ , groin, ___ , axilla
* mild ___ effect
* safest for ___ term use
- hydrocortisone
- face, genitals
- anti-inflammatory
- long
Topical Calcineurin Inhibitors
- MOA: blocks ___ cytokine genes
- ___ and ___
- considered ___ line treatment
- can be used on ___ area
- equivalent to ___ corts
- no risk of ___
- ___ use only
- $$$
- pro-inflammatory
- pimecrolimus and tacrolimus
- 2nd
- any
- atrophy
- intermittent
Crisaborole 2% Ointment
- mild-mode AD
- non-steroidal - ___ - 4 inhibitor
- good for patients who are scared of steroids
- BID for ___ days
- $$$
- phosphodiesterase
- 28 days
Dupilumab
Dupixent
* MOA: Human monoclonal antibody against ___ receptor alpha. Inhibits ___ and ___ signalling
* administered ___ every ___ weeks
* first biologic indicated for mod-severe AD for ages ___ +
- IL-4, IL-4, IL-13
- SC, 2 weeks
- 12+
Upadacitinib
Rinvoq
* moderate to severe AD
* MOA: ___ inhibitor
* Mediates signaling of cytokines and ___
* higher rates of major __ events and ___
- Janus kinase (JAK)
- growth factors
- CV, thrombosis